Effect observation of ulinastatin on blood infection patients with systemic inflammatory response

Objective To observe the clinical effect of ulinastatin in treatment of patients with blood infection and its influence on systemic inflammatory response. Methods 27 cases in ICU with blood infection etiologically were randomly divided into trial group of 14 and control group of 13. Both groups received the same routine treatment,while the trial group basing on the control group was added ulinastatin. Both groups had been treated for 7 days. Observed the effect of 2 groups. The acute physiology and chronic health evaluation Ⅱ( APACHEⅡ) score was estimated before and after the treatment in all the patients,and their blood was tested for determination of C-reactive protein( CRP) and procalcitonin( PCT) levels. Results Compared with the indexes before treatment,all of them in the 2 groups were decreased significantly after treatment. Compared with the control group,in the trial group,the APACHEⅡ scores( 13. 9 ± 4. 2 vs. 17. 8 ± 5. 7) 、CRP( mg/L: 9. 8 ± 2. 6 vs. 13. 4 ± 3. 1) 、PCT( ng / ml: 3. 7 ± 1. 8 vs. 8. 5 ± 1. 3) were declined more obviously,the differences were statistically significant( P 0. 05). Conclusion Ulinastatin can down-regulate the degree of acute inflammatory response of patients with blood infection and improve their prognosis.